Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer with PD-L1 ≥ 1 %: A subgroup analysis from the EMPOWER-Lung 3 part 2 trial.

MLA

Baramidze, Ana, et al. “Cemiplimab plus Chemotherapy versus Chemotherapy Alone in Non-Small Cell Lung Cancer with PD-L1 ≥ 1 %: A Subgroup Analysis from the EMPOWER-Lung 3 Part 2 Trial.” Lung Cancer (Amsterdam, Netherlands), vol. 193, July 2024, p. 107821. EBSCOhost, https://doi.org/10.1016/j.lungcan.2024.107821.

APA

Baramidze, A., Makharadze, T., Gogishvili, M., Melkadze, T., Giorgadze, D., Penkov, K., Laktionov, K., Nemsadze, G., Nechaeva, M., Rozhkova, I., Kalinka, E., Ag McIntyre, D., Perez, J., Kaul, M., Quek, R. G. W., Seebach, F., Rietschel, P., & Pouliot, J.-F. (2024). Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer with PD-L1 ≥ 1 %: A subgroup analysis from the EMPOWER-Lung 3 part 2 trial. Lung Cancer (Amsterdam, Netherlands), 193, 107821. https://doi.org/10.1016/j.lungcan.2024.107821

Chicago

Baramidze, Ana, Tamta Makharadze, Miranda Gogishvili, Tamar Melkadze, Davit Giorgadze, Konstantin Penkov, Konstantin Laktionov, et al. 2024. “Cemiplimab plus Chemotherapy versus Chemotherapy Alone in Non-Small Cell Lung Cancer with PD-L1 ≥ 1 %: A Subgroup Analysis from the EMPOWER-Lung 3 Part 2 Trial.” Lung Cancer (Amsterdam, Netherlands) 193 (July): 107821. doi:10.1016/j.lungcan.2024.107821.